Dyax Corp. Issued Fifth U.S. Patent in Its Phage Display Patent Portfolio
Tuesday January 10, 7:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2006--Dyax Corp. (Nasdaq:DYAX - News) announced today that the United States Patent and Trademark office issued U.S. Patent No. 6,979,538, Dyax's fifth U.S. patent covering its proprietary Phage Display technology. This new patent provides Dyax with additional patent claims that cover methods for displaying antibodies on filamentous bacteriophage. In addition to its five U.S. patents, Dyax holds several issued patents for Phage Display in Canada and Israel, with pending applications in other countries.
"This recently issued patent adds to Dyax's already dominant patent position in the phage display field. Our discovery technology platform continues to provide Dyax and our collaborators the ability to take almost any target of interest and identify novel compounds that selectively bind to it," said Ivana Magovcevic-Liebisch, General Counsel and Executive Vice President, Corporate Communications of Dyax Corp. "For example, our human antibody phage display libraries can be screened against a selected target to identify high-affinity antibodies that can be developed as new therapeutics."
About Dyax
Dyax Corp. is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on cancer and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. In its joint venture with Genzyme Corporation, Dyax has successfully completed two Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). A third Phase II trial is nearing completion, and a pivotal Phase III trial is ongoing. Independently, Dyax has successfully completed a Phase I/II trial of DX-88 for the prevention of blood loss during heart surgery (CABG procedures) and is in partnering discussions for further development of DX-88 in this indication. DX-88 has orphan drug designation in the US and EU, as well as Fast Track designation in the US, for the treatment of HAE.
Dyax identified DX-88 and other compounds in its pipeline using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages its technology broadly with over 75 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Dyax Disclaimer
This press release contains forward-looking statements, including statements regarding the extent of Dyax's patent portfolio and its potential for the identification of novel compounds. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the extent of Dyax's patent portfolio and its potential for the identification of novel compounds include the risks that: Dyax may not be able to obtain and maintain intellectual property protection for its Phage Display technology; others may develop technologies superior to Dyax's Phage Display technology; and Dyax is subject to other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com. Dyax and the Dyax logo are the registered trademarks of Dyax Corp. |
